News
November 29th, 2022
Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder
October 29th, 2020
Mebias Discovery Receives Grant from NIDA to Advance MEB1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder
October 14th, 2019
Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell Signaling-Pathway Selective GPCR Drug Discovery Platform
JULY 19TH, 2019
Philadelphia biopharm firm developing a new type of pain medicine raises $3.5M
September 15th, 2018
MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate
April 4th, 2018
NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic
December 5th, 2017
‘Biased’ opioids could yield safer pain relief
New compounds activate opioid receptor in a way that protects breathing
October 19th, 2017
Mebias’ mu opioids best morphine, Trevena drug in preclinical studies
October 16th, 2017
MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC